Trial Profile
A Phase 4, Open-label, Single-Arm Study of Brentuximab Vedotin in Patients With Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 20 Sep 2023
Price :
$35
*
At a glance
- Drugs Brentuximab vedotin (Primary)
- Indications Anaplastic large cell lymphoma
- Focus Therapeutic Use
- Sponsors Takeda Development Center Americas; Takeda Oncology
- 30 Sep 2021 Planned End Date changed from 10 Jan 2022 to 4 Oct 2024.
- 02 Aug 2021 Planned End Date changed from 10 Jun 2021 to 10 Jan 2022.
- 08 Jan 2021 Planned End Date changed from 1 Apr 2021 to 10 Jun 2021.